Concerning previous treatment strategy challenges, immunomodulators are novel treatment agents acting by downregulating the immune system and decreasing inflammatory mediators such as TNF-α, IL-17, and IL-23, which are crucial factors for developing follicular disorders like DCS [9]. The gene discussed is IL17A; the disease is folliculitis.